Method of inhibiting cancer cell proliferation, proliferation inhibitor and screening method
The present invention provides a method of inhibiting cancer cell proliferation by suppressing a function of ZNF143, a cancer cell proliferation inhibitor containing as an active ingredient a substance capable of inhibiting a function of ZNF143, like a ZNF143-specific siRNA, a prophylactic and/or therapeutic drug for cancer, a method of detecting cancer cells, a diagnostic reagent for cancer, a vector and transformant cell incorporating the vector, and a screening method for a substance possessing cancer cell proliferation inhibitory activity with the amount of inhibition of the binding of ZNF143 protein as an index.
1. A method of inhibiting cancer cell proliferation in a mammal, which method comprises suppressing a function of ZNF143 by administering an effective amount of an agent consisting of a polynucleotide, which is a nucleotide that induces an RNA interference that targets a ZNF143 gene or antisense nucleotide that targets the ZNF143 gene and which comprises a nucleotide sequence complementary to a nucleotide sequence that encodes ZNF143 or a partial sequence thereof with 15 consecutive bases or more, or an expression vector capable of expressing the polynucleotide, and a pharmaceutically acceptable carrier to a cancer cell of the mammal.
2. The method according to claim 1 , wherein the nucleotide that induces an RNA interference is siRNA and shRNA.
3. The method according to claim 1 , wherein the polynucleotide is a double-stranded RNA comprising a nucleotide sequence complementary to the nucleotide sequence shown by SEQ ID NO: 6 or 8 or a partial sequence thereof with 21 consecutive bases or more.
4. The method according to claim 1 , wherein the polynucleotide is a double-stranded RNA comprising a polynucleotide comprising the nucleotide sequence shown by any of SEQ ID NO: 1 to 3 or a partial sequence thereof with 21 to 30 consecutive bases, and a polynucleotide complementary to the polynucleotide.
5. A method of inhibiting cancer cell proliferation in a mammal, which method comprises suppressing a function of ZNF143 by administering an effective amount of an agent consisting of a polynucleotide comprising any ZNF143-binding nucleotide sequence selected from among the following nucleotide sequences, or an expression vector capable of expressing the polynucleotide, and a pharmaceutically acceptable carrier to a cancer cell of a mammal:
(1) the nucleotide sequence shown by SEQ ID NO: 4; and
(2) a nucleotide sequence having an identity of 60% or more to the nucleotide sequence shown by SEQ ID NO: 4, wherein the 4th, 5th, and 6th cytosines of the nucleotide sequence shown by SEQ ID NO: 4 are conserved, and wherein the 13th nucleotide is cytosine or guanine.
6. The method according to claim 1 , wherein the cancer is selected from the group consisting of colorectal cancer, lung cancer, ovarian cancer, breast cancer, gall bladder cancer, prostatic cancer and uterine cervical cancer.
7. The method according to claim 5 , wherein the cancer is selected from the group consisting of colorectal cancer, lung cancer, ovarian cancer, breast cancer, gall bladder cancer, prostatic cancer and uterine cervical cancer.
8. The method according to claim 1 , which method terminates the cell cycle of cancer cells in the G2 phase.
9. The method according to claim 5 , which method terminates the cell cycle of cancer cells in the G2 phase.
10. A therapeutic method for cancer comprising administering an effective amount of the agent consisting of a polynucleotide, which is a nucleotide that induces an RNA interference that targets a ZNF143 gene or antisense nucleotide that targets the ZNF143 gene and which comprises a nucleotide sequence complementary to a nucleotide sequence that encodes ZNF143 or a partial sequence thereof with 15 consecutive bases or more, or an expression vector capable of expressing the polynucleotide and a pharmaceutically acceptable carrier.
11. The method according to claim 10 , wherein the nucleotide that induces an RNA interference is siRNA or shRNA.
12. The method according to claim 10 , wherein the polynucleotide is a double-stranded RNA comprising the nucleotide sequence complementary to the nucleotide sequence shown by any of SEQ ID NO: 6 to 8 or a partial sequence thereof with 21 consecutive bases or more.
13. The method according to claim 10 , wherein the polynucleotide is a double-stranded RNA comprising a polynucleotide comprising the nucleotide sequence shown by any of SEQ ID NO: 1 to 3 or a partial sequence thereof with 21 to 30 consecutive bases, and a polynucleotide complementary to the polynucleotide.
14. The method according to claim 10 , wherein the cancer is selected from the group consisting of colorectal cancer, lung cancer, ovarian cancer, breast cancer, gall bladder cancer, prostatic cancer and uterine cervical cancer.
15. A therapeutic method for cancer in a mammal, which method comprises administering to the mammal an effective amount of an agent consisting of a polynucleotide comprising any ZNF143-binding nucleotide sequence selected from among the following nucleotide sequences, or an expression vector capable of expressing the polynucleotide, and a pharmaceutically acceptable carrier:
(1) the nucleotide sequence shown by SEQ ID NO: 4; and
(2) a nucleotide sequence having an identity of 60% or more to the nucleotide sequence shown by SEQ ID NO: 4, wherein the 4th, 5th, and 6th cytosines of the nucleotide sequence shown by SEQ ID NO: 4 are conserved, and wherein the 13th nucleotide is cytosine or guanine.
16. The method according to claim 15 , wherein the cancer is selected from the group consisting of colorectal cancer, lung cancer, ovarian cancer, breast cancer, gall bladder cancer, prostatic cancer and uterine cervical cancer.